Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells

Biochemical Pharmacology

Volumn 85, Issue 3, 2013, Pages 325-334

  Wu, Chung Pu ^a,d   Sim, Hong May ^c   Huang, Yang Hui ^a   Liu, Yen Chen ^b   Hsiao, Sung Han ^a   Cheng, Hsing Wen ^a   Li, Yan Qing ^a   Ambudkar, Suresh V ^c   Hsu, Sheng Chieh ^a,b,d  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NONE   (Taiwan)

Author keywords

ABC proteins; ABCG2; BRAF(V600E) mutant; Multidrug resistance; Vemurafenib

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C1; ADENOSINE TRIPHOSPHATASE; B RAF KINASE; BREAST CANCER RESISTANCE PROTEIN; DOXORUBICIN; ETOPOSIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; TARIQUIDAR; TOPOTECAN; UNCLASSIFIED DRUG; VEMURAFENIB;

ARTICLE; BREAST CANCER; CANCER RESISTANCE; COLON CANCER; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

EID: 84872679733     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.11.003     Document Type: Article

References (50)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. C.M. Balch, J.E. Gershenwald, S.J. Soong, J.F. Thompson, M.B. Atkins, and D.R. Byrd Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 2009 6199 6206
3. J.A. McCubrey, L.S. Steelman, S.L. Abrams, J.T. Lee, F. Chang, and F.E. Bertrand Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance Adv Enzyme Regul 46 2006 249 279
4. P.T. Wan, M.J. Garnett, S.M. Roe, S. Lee, D. Niculescu-Duvaz, and V.M. Good Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 2004 855 867
5. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, and S. Clegg Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
6. H.T. Arkenau, R. Kefford, and G.V. Long Targeting BRAF for patients with melanoma Br J Cancer 104 2011 392 398
7. G. Bollag, P. Hirth, J. Tsai, J. Zhang, P.N. Ibrahim, and H. Cho Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 467 2010 596 599
8. J.T. Lee, L. Li, P.A. Brafford, M. van den Eijnden, M.B. Halloran, and K. Sproesser PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas Pigment Cell Melanoma Res 23 2010 820 827
9. J. Tsai, J.T. Lee, W. Wang, J. Zhang, H. Cho, and S. Mamo Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity Proc Natl Acad Sci U S A 105 2008 3041 3046
10. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, and J. Larkin Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
11. K.T. Flaherty, I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, and J.A. Sosman Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
12. S. Kopetz, P.M. Hoff, J.S. Morris, R.A. Wolff, C. Eng, and K.Y. Glover Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance J Clin Oncol 28 2010 453 459
13. A.D. Roth, S. Tejpar, M. Delorenzi, P. Yan, R. Fiocca, and D. Klingbiel Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial J Clin Oncol 28 2010 466 474
14. M.N. Nikiforova, E.T. Kimura, M. Gandhi, P.W. Biddinger, J.A. Knauf, and F. Basolo BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas J Clin Endocrinol Metab 88 2003 5399 9404
15. C.M. Johannessen, J.S. Boehm, S.Y. Kim, S.R. Thomas, L. Wardwell, and L.A. Johnson COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Nature 468 2010 968 972
16. C. Montagut, S.V. Sharma, T. Shioda, U. McDermott, M. Ulman, and L.E. Ulkus Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma Cancer Res 68 2008 4853 4861
17. R. Nazarian, H. Shi, Q. Wang, X. Kong, R.C. Koya, and H. Lee Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 468 2010 973 977
18. F. Su, W.D. Bradley, Q. Wang, H. Yang, L. Xu, and B. Higgins Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation Cancer Res 72 2012 969 978
19. V. Yadav, X. Zhang, J. Liu, S. Estrem, S. Li, and X.Q. Gong Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras Mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma J Biol Chem 287 2012 28087 28098
20. P.I. Poulikakos, Y. Persaud, M. Janakiraman, X. Kong, C. Ng, and G. Moriceau RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) Nature 480 2011 387 390
21. J. Villanueva, A. Vultur, J.T. Lee, R. Somasundaram, M. Fukunaga-Kalabis, and A.K. Cipolla Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K Cancer Cell 18 2010 683 695
22. H. Shi, X. Kong, A. Ribas, and R.S. Lo Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition Cancer Res 71 2011 5067 5074
23. A. Prahallad, C. Sun, S. Huang, F. Di Nicolantonio, R. Salazar, and D. Zecchin Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR Nature 483 2012 100 103
24. C.P. Wu, C.H. Hsieh, and Y.S. Wu The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy Mol Pharm 8 2011 1996 2011
25. C.P. Wu, S. Shukla, A.M. Calcagno, M.D. Hall, M.M. Gottesman, and S.V. Ambudkar Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter Mol Cancer Ther 6 2007 3287 3296
26. Y. Honjo, C.A. Hrycyna, Q.W. Yan, W.Y. Medina-Perez, R.W. Robey, and A. van de Laar Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells Cancer Res 61 2001 6635 6639
27. R.W. Robey, W.Y. Medina-Perez, K. Nishiyama, T. Lahusen, K. Miyake, and T. Litman Overexpression of the ATP-binding cassette half-transporter, ABCG2 (MXR/BCRP/ABCP1), in flavopiridol-resistant human breast cancer cells Clin Cancer Res 7 2001 145 152
28. D.W. Shen, A. Fojo, J.E. Chin, I.B. Roninson, N. Richert, and I. Pastan Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification Science 232 1986 643 645
29. R.W. Robey, K. Steadman, O. Polgar, K. Morisaki, M. Blayney, and P. Mistry Pheophorbide a is a specific probe for ABCG2 function and inhibition Cancer Res 64 2004 1242 1246
30. S.V. Ambudkar Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells Methods Enzymol 292 1998 504 514
31. S. Shukla, V. Rai, D. Banerjee, and R. Prasad Characterization of Cdr1p, a major multidrug efflux protein of Candida albicans: purified protein is amenable to intrinsic fluorescence analysis Biochemistry 45 2006 2425 2435
32. Z.E. Sauna, and S.V. Ambudkar Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein Proc Natl Acad Sci U S A 97 2000 2515 2520
33. C.P. Wu, A.M. Calcagno, S.B. Hladky, S.V. Ambudkar, and M.A. Barrand Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5) FEBS J 272 2005 4725 4740
34. S.V. Ambudkar, C.O. Cardarelli, I. Pashinsky, and W.D. Stein Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein J Biol Chem 272 1997 21160 21166
35. C. Hegedus, C. Ozvegy-Laczka, G. Szakacs, and B. Sarkadi Interaction of ABC multidrug transporters with anticancer protein kinase inhibitors: substrates and/or inhibitors Curr Cancer Drug Targets 9 2009 252 272
36. R.K. Mittapalli, S. Vaidhyanathan, R. Sane, and W.F. Elmquist Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032) J Pharmacol Exp Ther 342 2012 33 40
37. S. Shukla, C.P. Wu, and S.V. Ambudkar Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges Expert Opin Drug Metab Toxicol 4 2008 205 223
38. S. Shukla, Z.S. Chen, and S.V. Ambudkar Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance Drug Resist Updat 15 2012 70 80
39. C. Ozvegy-Laczka, J. Cserepes, N.B. Elkind, and B. Sarkadi Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters Drug Resist Updat 8 2005 15 26
40. C. Hegedus, C. Ozvegy-Laczka, A. Apati, M. Magocsi, K. Nemet, and L. Orfi Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties Br J Pharmacol 158 2009 1153 1164
41. C.L. Dai, A.K. Tiwari, C.P. Wu, X.D. Su, S.R. Wang, and D.G. Liu Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2 Cancer Res 68 2008 7905 7914
42. Y.J. Mi, Y.J. Liang, H.B. Huang, H.Y. Zhao, C.P. Wu, and F. Wang Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters Cancer Res 70 2010 7981 7991
43. C.F. Stewart, M. Leggas, J.D. Schuetz, J.C. Panetta, P.J. Cheshire, and J. Peterson Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice Cancer Res 64 2004 7491 7499
44. J.A. Ludwig, G. Szakacs, S.E. Martin, B.F. Chu, C. Cardarelli, and Z.E. Sauna Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer Cancer Res 66 2006 4808 4815
45. L. Candeil, I. Gourdier, D. Peyron, N. Vezzio, V. Copois, and F. Bibeau ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases Int J Cancer 109 2004 848 854
46. H.G. Liu, Y.F. Pan, J. You, O.C. Wang, K.T. Huang, and X.H. Zhang Expression of ABCG2 and its significance in colorectal cancer Asian Pac J Cancer Prev 11 2010 845 848
47. J.P. Lopez, J. Wang-Rodriguez, C. Chang, J.S. Chen, F.S. Pardo, and J. Aguilera Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines Arch Otolaryngol Head Neck Surg 133 2007 1022 1027
48. X. Zheng, D. Cui, S. Xu, G. Brabant, and M. Derwahl Doxorubicin fails to eradicate cancer stem cells derived from anaplastic thyroid carcinoma cells: characterization of resistant cells Int J Oncol 37 2010 307 315
49. E. Monzani, F. Facchetti, E. Galmozzi, E. Corsini, A. Benetti, and C. Cavazzin Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential Eur J Cancer 43 2007 935 946
50. Q. Mao, and J.D. Unadkat Role of the breast cancer resistance protein (ABCG2) in drug transport AAPS J 7 2005 E118 E133